dr. hammers on the long-term benefits of the checkmate-214 study in rcc
Published 6 years ago • 177 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
1:51
dr. hammers on study of hyperacute renal immunotherapy in rcc
-
0:56
dr. hammers on next steps with immunotherapy in rcc
-
1:17
dr. hammers on the future of immunotherapy in rcc
-
1:37
dr. amin on rationale for checkmate-214 trial in rcc
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
1:21
dr. powles on the 42-month follow-up data from the checkmate-214 trial in rcc
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
1:20
dr. hammers on immunotherapy combinations in kidney cancer
-
1:54
checkmate 214 trial in rcc updates
-
1:37
dr. hammers on combinations of ido and pd-1 inhibitors in rcc
-
1:14
dr. choueiri on significance of checkmate-025 study for rcc
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
4:05
long-term rcc data with nivolumab
-
5:06
phase 3 checkmate - 214